Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKNE-MYCIN vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Topical treatment of acne vulgaris
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Topical application of 2% solution twice daily to affected areas.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Not systemically absorbed to a clinically significant degree after topical application. If absorbed, erythromycin is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Bound primarily to albumin (10-20%)
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
0.2-0.3 L/kg, indicating limited extravascular distribution (primarily extracellular fluid)
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Topical: 2-5% (minimal systemic absorption); oral: 75-85%
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
No dosage adjustment required for topical use; systemic absorption negligible.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
No dosage adjustment required for topical use; systemic absorption negligible.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Safety and efficacy not established in children under 12 years; for age ≥12 years, same as adult dosing.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
No specific adjustments; use with caution due to potential increased skin sensitivity.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
None
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
For external use only; avoid contact with eyes, mouth, and mucous membranes. May cause skin irritation, burning, stinging, or dryness. Reported cases of pseudomembranous colitis with topical use (rare). Use with caution in patients with hepatic impairment if significant systemic absorption occurs. Cross-resistance with other macrolides may develop. Use during pregnancy only if clearly needed (category B).
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Hypersensitivity to erythromycin or any component of the formulation. Concurrent use with pimozide or ergot alkaloids (potential for QT prolongation and ergotism, though systemic absorption low).
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
No specific food interactions. Take with or without food. Avoid excessive intake of spicy or greasy foods, which may exacerbate acne.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with topical use, but risk cannot be completely excluded. First trimester: low risk, but use only if clearly needed. Second and third trimesters: generally considered safe with minimal systemic exposure.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Erythromycin is excreted in human milk in small amounts. Topical Akne-Mycin results in negligible systemic absorption, making significant infant exposure unlikely. M/P ratio not reported for topical use; oral erythromycin M/P ratio is approximately 0.5. Caution is advised, but use is generally compatible with breastfeeding.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
No dose adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not clinically relevant for topical Akne-Mycin due to minimal systemic absorption. Apply as directed regardless of pregnancy trimester.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
Akne-Mycin (erythromycin topical) is effective for mild to moderate acne vulgaris. It can be combined with benzoyl peroxide to reduce antibiotic resistance. Avoid use with other topical erythromycin products to prevent overuse. Monitor for local skin reactions like erythema, scaling, or itching.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Apply a thin layer to affected areas once or twice daily as directed.,Wash skin gently with mild soap and pat dry before application.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use more often than prescribed; overuse can increase irritation.,Inform your doctor if you develop severe redness, peeling, or discomfort.,Use sunscreen daily as this medication may increase sun sensitivity.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKNE-MYCIN vs ANEXSIA 7.5/650, answered by our medical review team.
AKNE-MYCIN is a Topical Antibiotic that works by Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKNE-MYCIN and ANEXSIA 7.5/650 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKNE-MYCIN is: Topical application of 2% solution twice daily to affected areas.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKNE-MYCIN and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKNE-MYCIN is classified as Category C. Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with . ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.